We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Oncotest and Debiopharm Announce a Successful Partnership
News

Oncotest and Debiopharm Announce a Successful Partnership

Oncotest and Debiopharm Announce a Successful Partnership
News

Oncotest and Debiopharm Announce a Successful Partnership

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Oncotest and Debiopharm Announce a Successful Partnership"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Oncotest GmbH and Debiopharm Group™ (Debiopharm) have announced the successful completion of the first biomarker projects at Oncotest.

In a recent study, pharmacological data was generated with Debiopharm’s investigational compound in Oncotest’s 3D assay system for patient-derived xenografts and correlated with the extensive Oncotest’s genomic and transcriptomic data.

The collaboration resulted in the identification of several predictive biomarkers candidates including a gene signature.

“We are enthusiastic to work with Debiopharm on these projects and are looking forward to continue and expand our collaboration. I am convinced that the concept of deriving predictive biomarkers for new drugs already in a preclinical setting will make an impact. Ultimately, it has a significant potential to lower the attrition rates in clinical trials. Today, with our new biomarker department and the characterization data available for our tumor models, Oncotest is ideally positioned in this area.” said Prof. Heiner Fiebig, Founder and CEO of Oncotest.

Dr. Hiroaki Tanaka, Personalized Medicine Director at Debiopharm added: “Reliable preclinical models are key success factors in drug development. We believe that technologies based on the direct use of patient tumors have a game-changer potential in translational research in oncology. We are happy to collaborate with Oncotest, a pioneer and a leader in the area, and we are looking forward to extending our partnership even further towards the achievement of personalized medicine.”

Advertisement